How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome - PubMed (original) (raw)

Multicenter Study

doi: 10.1097/MCG.0b013e318225f545.

Margaret A Brinich, Gail Geller, Krista Harrison, Janelle Highland, Katherine James, Patricia Marshall, Jennifer B McCormick, Jon Tilburt, Jean-Paul Achkar, Ruth M Farrell, Richard R Sharp

Affiliations

Multicenter Study

How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome

MaryBeth Mercer et al. J Clin Gastroenterol. 2012 Feb.

Abstract

Background: Patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) have access to a growing number of probiotic products marketed to improve digestive health. It is unclear how patients make decisions about probiotics and what role they expect their gastroenterologists to play as they consider using probiotics. Understanding patients' knowledge, attitudes and expectations of probiotics may help gastroenterologists engage patients in collaborative discussions about probiotics.

Study: Focus groups were conducted with patients with IBD and IBS at the Cleveland Clinic, Mayo Clinic, and Johns Hopkins University. Inductive analytic methods were used to identify common themes and draw interpretations from focus group narratives.

Results: One hundred thirty-six patients participated in 22 focus groups between March and August 2009. Patients viewed probiotics as an appealing alternative to pharmaceutical drugs and understood probiotics as a more "natural," low-risk therapeutic option. Many patients were hesitant to use them without consulting their gastroenterologists. Patients would weigh the risks and benefits of probiotics, their disease severity and satisfaction with current treatments when considering probiotic use.

Conclusions: Patients are interested in probiotics but have many unanswered questions about their use. Our findings suggest that patients with IBD and IBS will look to gastroenterologists and other clinicians as trustworthy advisors regarding the utility of probiotics as an alternative or supplement to pharmaceutical drugs. Gastroenterologists and other clinicians who care for patients with these diseases should be prepared to discuss the potential benefits and risks of probiotics and assist patients in making informed decisions about their use.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any conflicts of interest to disclose.

Similar articles

Cited by

References

    1. Granato D, Branco GF, Cruz AG, et al. Probiotic dairy products as functional food. Compr Rev Food Sci Food Saf. 2010;9:455–470. - PubMed
    1. Vanderhoof JA, Young R. Probiotics in the United States. Clin Infect Dis. 2008;46(Suppl 2):S67–72. - PubMed
    1. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med. 2007;15(1):30–37. - PubMed
    1. Li FX, Verhoef MJ, Best A, et al. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol. 2005;19(9):567–573. - PubMed
    1. Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: an internet survey. Can J Gastroenterol. 1999;13(4):321–332. - PubMed

Publication types

MeSH terms

LinkOut - more resources